80 related articles for article (PubMed ID: 25896603)
1. Pharmacokinetic interaction study combining lapatinib with vorinostat in rats.
Lin F; Wang S; Zhou Y; Wu C; Zou H; Geng P; Zhang Q; Zhang X
Pharmacology; 2015; 95(3-4):160-5. PubMed ID: 25896603
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
Yang X; Zhang Q; Chen M; Hu L
Xenobiotica; 2014 Nov; 44(11):1009-13. PubMed ID: 24831712
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.
McDonnel SJ; Tell LA; Murphy BG
J Vet Pharmacol Ther; 2014 Apr; 37(2):196-200. PubMed ID: 24236915
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Karbownik A; Szałek E; Sobańska K; Klupczynska A; Plewa S; Grabowski T; Wolc A; Moch M; Kokot ZJ; Grześkowiak E
Pharmacol Rep; 2018 Apr; 70(2):191-195. PubMed ID: 29471066
[TBL] [Abstract][Full Text] [Related]
5. Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats.
Wang Y; Tu S; Steffen D; Xiong M
J Pharm Pharm Sci; 2014; 17(4):583-602. PubMed ID: 25579435
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.
Patel K; Guichard SM; Jodrell DI
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Feb; 863(1):19-25. PubMed ID: 18221921
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Hudachek SF; Gustafson DL
Anticancer Drugs; 2013 Oct; 24(9):958-68. PubMed ID: 23928571
[TBL] [Abstract][Full Text] [Related]
8. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS.
Zhou Y; Wang S; Ding T; Wu M; Geng P; Zhang Q; Ma J
Drug Dev Ind Pharm; 2015; 41(12):1948-53. PubMed ID: 25632980
[TBL] [Abstract][Full Text] [Related]
10. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.
Parise RA; Holleran JL; Beumer JH; Ramalingam S; Egorin MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(2):108-15. PubMed ID: 16725386
[TBL] [Abstract][Full Text] [Related]
11. Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma.
Musijowski J; Filist M; Rudzki PJ
Acta Pol Pharm; 2014; 71(6):1029-36. PubMed ID: 25745775
[TBL] [Abstract][Full Text] [Related]
12. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Kim JY; Shim G; Choi HW; Park J; Chung SW; Kim S; Kim K; Kwon IC; Kim CW; Kim SY; Yang VC; Oh YK; Byun Y
Biomaterials; 2012 Jun; 33(17):4424-30. PubMed ID: 22425551
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes in rat serum after administration of suberoylanilide hydroxamic acid and discriminated by SVM.
Yu J; Wu H; Lin Z; Su K; Zhang J; Sun F; Wang X; Wen C; Cao H; Hu L
Hum Exp Toxicol; 2017 Dec; 36(12):1286-1294. PubMed ID: 28084089
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
15. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.
Du L; Musson DG; Wang AQ
Rapid Commun Mass Spectrom; 2005; 19(13):1779-87. PubMed ID: 15945019
[TBL] [Abstract][Full Text] [Related]
16. Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.
Kumar V; Lal J; Singh MM; Gupta RC
Contraception; 2006 Aug; 74(2):165-73. PubMed ID: 16860055
[TBL] [Abstract][Full Text] [Related]
17. Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats.
Kushwaha HN; Misra A; Gautam N; Singh Y; Kumar H; Siddiqui HH; Singh SK
Drug Res (Stuttg); 2013 Jun; 63(6):282-8. PubMed ID: 23558601
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of suberoylanilide hydroxamic acid (Vorinostat) in the treatment of canine corneal fibrosis.
Bosiack AP; Giuliano EA; Gupta R; Mohan RR
Vet Ophthalmol; 2012 Sep; 15(5):307-14. PubMed ID: 22212187
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies.
Yeo P; Xin L; Goh E; New LS; Zeng P; Wu X; Venkatesh P; Kantharaj E
Biomed Chromatogr; 2007 Feb; 21(2):184-9. PubMed ID: 17221921
[TBL] [Abstract][Full Text] [Related]
20. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
Wise LD; Turner KJ; Kerr JS
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):57-68. PubMed ID: 17294457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
